Bayer's Pipeline Momentum Meets a Missouri Courtroom and a Cautious Quarter
Published on 10/01/2026 at 10:20 | Editorial boerse-global.de
European equities stumbled into the fourth quarter, with the DAX sliding on Thursday as rising energy costs and renewed inflation anxiety weighed on blue chips. Bayer was caught in the downdraft, shedding 2.0 percent to close at EUR 46.79, in step with the benchmark's broader retreat.
The timing is awkward. Macro headlines are drowning out genuine operational progress at the Leverkusen-based group, leaving investors to weigh whether a string of pipeline wins can keep the stock on track despite the gloomy market mood.
FDA Grants Priority Review for Lynkuet
Earlier this week, the company disclosed a meaningful US regulatory milestone. On Monday, the FDA accepted the supplemental New Drug Application (sNDA) for Lynkuet (elinzanetant) and handed the filing Priority Review designation.
The submission covers a broader indication: the treatment of moderate-to-severe vasomotor symptoms — hot flashes, in common parlance — in women undergoing endocrine therapy for hormone receptor-positive breast cancer. Data from the Phase III OASIS 4 trial underpin the filing. Priority status shortens the FDA's standard evaluation window, a recognition that the therapy could close a substantial care gap for these cancer patients.
BlueRock Adds Orphan Designations on Two Continents
The pipeline momentum extends beyond Lynkuet. Subsidiary BlueRock Therapeutics secured Orphan Drug status from the FDA on Wednesday for its cell therapy candidate Lemiretprocel, covering retinitis pigmentosa and cone-rod dystrophy. The EMA followed with its own orphan designation for certain inherited retinal diseases. Such labels carry expanded market and development privileges.
Should investors sell immediately? Or is it worth buying Bayer?
Bayer also shored up its financial flexibility on 23 September by placing hybrid bonds. Against that backdrop, Deutsche Bank Research reiterated its Buy rating with a price target of EUR 60.
A Missouri Glyphosate Trial Tests a New Legal Theory
Running parallel to the market-wide weakness, legal risk in the United States has returned to center stage. In Missouri, a glyphosate trial against subsidiary Monsanto got underway on Wednesday.
Three plaintiffs allege the company failed to adequately test the herbicide Roundup before bringing it to market. Observers view the case as a bellwether because it rests on a different line of argument than the previous warning-label claims, making it a directional test for future liability exposure.
Should the Missouri case widen Monsanto's liability, the group faces further financial setbacks. A defeat built on novel legal theories could seriously undermine confidence in any final cleanup of the legacy litigation.
Amundi Trims Its Stake
Institutional investors are already turning cautious. A voting rights notification on Tuesday showed asset manager Amundi reducing its holding in Bayer. After crossing a threshold on 23 September, its voting share fell from 3.04 percent to 2.90 percent. Further withdrawals of institutional capital threaten to cap the share price even if operating data hold up.
The macro backdrop for cyclical agrochemical products remains fragile as well. Higher interest rates make refinancing more expensive, while volatile end markets squeeze margins.
Deutsche Bank Sees a Softer Third Quarter
Attention now shifts to how resilient the operating business really is. The focus falls squarely on the earnings power of the Crop Science division, which has been shaped in recent quarters by swings in global commodity and crop protection markets.
Bayer at a turning point? This analysis reveals what investors need to know now.
Deutsche Bank Research addressed that setup on Tuesday in a sector note. Analyst Virginie Boucher-Ferte expects operating revenue growth of 1.3 percent year over year for the upcoming third quarter. At the same time, she models a 10 percent decline in operating profit, largely because favorable one-off effects had flattered the prior-year quarter in the agricultural business.
Whether the earnings base is strong enough to absorb the persistent legal uncertainty is the real litmus test for the group's valuation. Market participants must judge whether structural profitability in the core business is high enough to build financial buffers for potential settlements.
Chart Levels and the November Print
The technical picture stays constructive as long as the stock does not slip below key trend lines. At EUR 47.75 — Wednesday's close — the shares remain comfortably above the 200-day moving average of EUR 43.00. If buyers defend that level, the medium-term uptrend holds; a decisive break below it would likely hand the bears the upper hand.
Year to date, the stock is still up 26 percent despite Thursday's pullback. The next hard catalyst is already on the calendar: Bayer publishes its full third-quarter results on 3 November. That release will show whether operations can support expectations — or whether the US litigation seizes the narrative once again.
Ad
Bayer Stock: New Analysis - 1 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
